News

Our Fall Clinical Forum highlights Brenzavvy (bexagliflozin), a lower-cost option for type 2 diabetes, and shares clinical recommendations for newly approved therapies.

We’re committed to offering timely, clinically relevant information about newly approved medications. These updates are designed to assist with the development of criteria for clinical review, prior authorization, or utilization management strategies.

Biologic medications and their biosimilar counterparts are transforming how we treat complex health conditions. Understanding the differences between the two can help patients and providers make informed decisions about treatment options. Today, we take a closer look at the evolving biosimilar market, share updates regarding Humira and its biosimilar counterparts, and introduce emerging biosimilar products for Stelara.

Learn more about the pharmacists at PDMI for American Pharmacists Month.

Learn more about the pharmacists at PDMI for American Pharmacists Month.